Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage
- PMID: 2758416
Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage
Abstract
The H-35 rat hepatoma, a cell line which is relatively resistant to the classical anthracycline antibiotics such as Adriamycin [the concentration of drug which inhibits cell proliferation by 5090 (IC50) = 2.5 microM] and daunorubicin (IC50 of 0.5 microM), is markedly more sensitive to the 4-demethoxydaunorubicin derivative, idarubicin (IC50 of 0.025 microM). In contrast to daunorubicin, which has previously been shown to inhibit hepatoma cell proliferation in the absence of perceptible DNA cleavage, idarubicin induces concentration-dependent DNA damage which may account for its enhanced capacity to inhibit proliferation of the rat hepatoma. Free radical scavengers fail to interfere with inhibition of cell proliferation induced by idarubicin. Damage to the cell membrane or alterations in mitochondrial integrity do not appear to represent components of idarubicin toxicity in this tumor cell line. Inhibition of DNA synthesis by idarubicin parallels inhibition of cell growth; however, sensitivity of DNA synthesis to idarubicin is significantly less than that for cell proliferation (IC50 values of 0.5 microM and 0.025 microM, respectively). It is postulated that the antiproliferative effects of idarubicin in the H-35 rat hepatoma model may be a consequence of alterations in DNA integrity which ultimately result in the inhibition of cellular biosynthetic processes.
Similar articles
-
Evidence for inhibition of growth related to compromised DNA synthesis in the interaction of daunorubicin with H-35 rat hepatoma.Cancer Res. 1988 May 1;48(9):2404-11. Cancer Res. 1988. PMID: 3356005
-
Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line.Cancer Chemother Pharmacol. 1998;41(5):361-9. doi: 10.1007/s002800050752. Cancer Chemother Pharmacol. 1998. PMID: 9523731
-
Antiproliferative effects of N1,N4-dibenzylputrescine in human and rodent tumor cells.Cell Mol Biol (Noisy-le-grand). 1998 Jun;44(4):615-25. Cell Mol Biol (Noisy-le-grand). 1998. PMID: 9678897
-
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.Biochem Pharmacol. 1999 Apr 1;57(7):727-41. doi: 10.1016/s0006-2952(98)00307-4. Biochem Pharmacol. 1999. PMID: 10075079 Review.
-
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.Semin Oncol. 1989 Feb;16(1 Suppl 2):2-9. Semin Oncol. 1989. PMID: 2648580 Review. No abstract available.
Cited by
-
Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.Ann Hematol. 1992 Nov;65(5):206-12. doi: 10.1007/BF01703946. Ann Hematol. 1992. PMID: 1360820
-
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010. Drugs. 1991. PMID: 1723369 Review.